Rat Aplnr (Apelin receptor) ELISA Kit

The predicted protein encoded by the APJ gene discovered in 1993 was originally classified as a class A G protein-coupled orphan receptor but was subsequently paired with a novel peptide ligand, apelin-36 in 1998. Substantial research identified a family of shorter peptides activating the apelin receptor, including apelin-17, apelin-13, and [Pyr(1)]apelin-13, with the latter peptide predominating in human plasma and cardiovascular system. A range of pharmacological tools have been developed, including radiolabeled ligands, analogs with improved plasma stability, peptides, and small molecules including biased agonists and antagonists, leading to the recommendation that the APJ gene be renamed APLNR and encode the apelin receptor protein. Recently, a second endogenous ligand has been identified and called Elabela/Toddler, a 54-amino acid peptide originally identified in the genomes of fish and humans but misclassified as noncoding. This precursor is also able to be cleaved to shorter sequences (32, 21, and 11 amino acids), and all are able to activate the apelin receptor and are blocked by apelin receptor antagonists. This review summarizes the pharmacology of these ligands and the apelin receptor, highlights the emerging physiologic and pathophysiological roles in a number of diseases, and recommends that Elabela/Toddler is a second endogenous peptide ligand of the apelin receptor protein.

ELABELA (ELA), previously classified as a "noncoding" RNA, is a new endogenous peptidic ligand of apelin receptor (APJ/APLNR), a class A (rhodopsin-like) G protein-coupled receptor. It has been identified to play a crucial role in diverse biological processes, especially in the normal and pathological cardiovascular system. In comparison with APJ's first ligand apelin, ELA may play a key role at different time points or heart regions. In this review, we summarized the roles of the ELA-APJ signaling pathway in cardiovascular system development and diseases.